Twin changes at AstraZeneca's MedImmune kick off this week's gallery, as well as jobs news from Europe
Peter Emtage has been promoted to VP, Immune Mediated Therapies, at MedImmune, the global biologics R&D subsidiary of AstraZeneca.
The role will focus on immune mediated therapies for cancer (IMT-C) and, said MedImmune, “the rapidly growing trend of [the company’s] IMT-C portfolio assets to be developed in combinations, across project team lines.”
Copyright - Unless otherwise stated all contents of this web site are © 2017 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
Welcome to in-PharmaTechnologist's monthly round up of who's been moving where in the small-molecule manufacturing world. The...
Eli Lilly is conducting several experiments on the International Space Station (ISS) US National Laboratory over the...
The world’s largest modular cGMP biopharmaceutical manufacturing facility came online this week in Wuhan, China.
Valeant, Rentschler, Celgene, MannKind, and Syngene are among those welcoming new leaders for 2016. Oh, and Turing...